NASDAQ:REPH - Recro Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.55 -0.08 (-1.42 %)
(As of 05/27/2018 09:32 AM ET)
Previous Close$5.55
Today's Range$5.2701 - $5.67
52-Week Range$5.00 - $13.05
Volume1.52 million shs
Average Volume656,529 shs
Market Capitalization$113.82 million
P/E Ratio-2.79
Dividend YieldN/A
Beta-0.75

About Recro Pharma (NASDAQ:REPH)

Recro Pharma logoRecro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Debt-to-Equity Ratio2.20
Current Ratio1.78
Quick Ratio1.55

Price-To-Earnings

Trailing P/E Ratio-2.79
Forward P/E Ratio-1.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.83 million
Price / Sales1.58
Cash FlowN/A
Price / CashN/A
Book Value$1.20 per share
Price / Book4.63

Profitability

EPS (Most Recent Fiscal Year)($1.99)
Net Income$-50,080,000.00
Net Margins-74.85%
Return on Equity-105.78%
Return on Assets-24.06%

Miscellaneous

Employees256
Outstanding Shares20,510,000

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma (NASDAQ:REPH) announced its quarterly earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.03. The specialty pharmaceutical company had revenue of $19.54 million for the quarter, compared to analyst estimates of $17.32 million. Recro Pharma had a negative net margin of 74.85% and a negative return on equity of 105.78%. View Recro Pharma's Earnings History.

What price target have analysts set for REPH?

7 brokers have issued 1-year target prices for Recro Pharma's shares. Their predictions range from $9.00 to $19.00. On average, they anticipate Recro Pharma's share price to reach $13.20 in the next year. View Analyst Ratings for Recro Pharma.

Who are some of Recro Pharma's key competitors?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, CEO, Pres & Director (Age 66)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 59)
  • Mr. Frederick H. Graff, Chief Commercial Officer (Age 68)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 41)
  • Mr. Randall J. Mack, Sr. VP of Devel. and Corp. Sec. (Age 53)

Has Recro Pharma been receiving favorable news coverage?

Media stories about REPH stock have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Recro Pharma earned a news impact score of 0.09 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 45.56 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BROADFIN CAPITAL, LLC (11.67%), BROADFIN CAPITAL, LLC (9.99%), Lyon Street Capital LLC (5.01%), BlackRock Inc. (4.60%), Sphera Funds Management LTD. (1.87%) and Millennium Management LLC (1.35%). Company insiders that own Recro Pharma stock include Alfred Altomari, Healthcare Master Fun Broadfin, James E Flynn, Karen Flynn, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp, Stewart Mccallum and Stonepine Capital Management,. View Institutional Ownership Trends for Recro Pharma.

Which major investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and Opus Point Partners Management LLC. Company insiders that have sold Recro Pharma company stock in the last year include Healthcare Master Fun Broadfin, James E Flynn, Scp Vitalife Partners (Israel) and Scp Vitalife Partners Ii Lp. View Insider Buying and Selling for Recro Pharma.

Which major investors are buying Recro Pharma stock?

REPH stock was bought by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Sphera Funds Management LTD., Millennium Management LLC, The Manufacturers Life Insurance Company , Schwab Charles Investment Management Inc., Engine Capital Management LLC, JPMorgan Chase & Co. and Bailard Inc.. Company insiders that have bought Recro Pharma stock in the last two years include Alfred Altomari, Healthcare Master Fun Broadfin, Karen Flynn and Stewart Mccallum. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $5.55.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $113.82 million and generates $71.83 million in revenue each year. The specialty pharmaceutical company earns $-50,080,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Recro Pharma employs 256 workers across the globe.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (REPH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  322
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Recro Pharma (NASDAQ:REPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Recro Pharma in the last 12 months. Their average twelve-month price target is $13.20, suggesting that the stock has a possible upside of 137.84%. The high price target for REPH is $19.00 and the low price target for REPH is $9.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.20$15.10$14.4167$13.50
Price Target Upside: 137.84% upside27.53% upside75.60% upside56.43% upside

Recro Pharma (NASDAQ:REPH) Consensus Price Target History

Price Target History for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/26/2018Roth CapitalSet Price TargetBuy$9.00N/AView Rating Details
5/25/2018OppenheimerSet Price TargetBuy$18.00HighView Rating Details
5/24/2018Piper Jaffray CompaniesLower Price TargetOverweight$17.00 ➝ $9.00HighView Rating Details
5/24/2018Janney Montgomery ScottLower Price TargetBuy ➝ Fair Value$21.00 ➝ $11.00HighView Rating Details
4/19/2018Berenberg BankInitiated CoverageBuyLowView Rating Details
2/14/2018CIBCInitiated CoverageOutperform ➝ Outperform$19.00HighView Rating Details
2/13/2018UBSInitiated CoverageOutperformHighView Rating Details
3/27/2017AegisReiterated RatingBuy$11.00LowView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$19.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Recro Pharma (NASDAQ:REPH) Earnings History and Estimates Chart

Earnings by Quarter for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.94)
2019 EPS Consensus Estimate: ($1.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.54)($0.54)($0.54)
Q2 20182($1.47)($0.56)($1.02)
Q3 20182($0.79)($0.68)($0.74)
Q4 20182($0.69)($0.61)($0.65)
Q1 20191($0.58)($0.58)($0.58)
Q2 20191($0.42)($0.42)($0.42)
Q3 20191($0.34)($0.34)($0.34)
Q4 20191($0.17)($0.17)($0.17)

Recro Pharma (NASDAQ REPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.68)($0.65)$17.32 million$19.54 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.85)($0.63)$12.88 million$19.04 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.75)($0.48)$13.93 million$17.11 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.54)($0.48)$14.90 million$16.93 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.5750)($0.42)$15.58 million$18.74 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.96)($0.81)$13.25 million$17.36 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.71)($0.50)$13.50 million$16.95 millionViewN/AView Earnings Details
8/11/2016Q2($0.78)($0.83)$18.70 million$17.30 millionViewN/AView Earnings Details
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details
3/24/2016Q4($0.43)$1.13$13.00 million$16.75 millionViewN/AView Earnings Details
11/13/2015Q3($0.20)($0.24)$16.54 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.17)$18.66 millionViewN/AView Earnings Details
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Recro Pharma (NASDAQ:REPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Recro Pharma (NASDAQ REPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 56.15%
Insider Trading History for Recro Pharma (NASDAQ:REPH)
Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ REPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/24/2018Healthcare Master Fun BroadfinMajor ShareholderSell188,000$5.81$1,092,280.00View SEC Filing  
3/13/2018Healthcare Master Fun BroadfinMajor ShareholderSell200,000$10.07$2,014,000.00View SEC Filing  
1/3/2018Scp Vitalife Partners (Israel)Major ShareholderSell12,964$8.88$115,120.32734,269View SEC Filing  
12/29/2017Scp Vitalife Partners Ii LpMajor ShareholderSell18,231$9.27$169,001.37View SEC Filing  
12/28/2017Scp Vitalife Partners (Israel)Major ShareholderSell1,980$9.44$18,691.20744,708View SEC Filing  
12/27/2017Scp Vitalife Partners Ii LpMajor ShareholderSell13,189$9.56$126,086.842,243,064View SEC Filing  
12/21/2017Healthcare Master Fun BroadfinMajor ShareholderSell76,000$9.87$750,120.00View SEC Filing  
12/13/2017Healthcare Master Fun BroadfinMajor ShareholderSell93,237$9.86$919,316.82View SEC Filing  
12/5/2017Healthcare Master Fun BroadfinMajor ShareholderSell100,000$10.00$1,000,000.00View SEC Filing  
11/30/2017Healthcare Master Fun BroadfinMajor ShareholderSell222,616$9.58$2,132,661.28View SEC Filing  
11/28/2017Healthcare Master Fun BroadfinMajor ShareholderSell47,549$9.64$458,372.36View SEC Filing  
11/24/2017Healthcare Master Fun BroadfinMajor ShareholderSell172,208$9.45$1,627,365.60View SEC Filing  
11/21/2017Healthcare Master Fun BroadfinMajor ShareholderSell102,440$9.50$973,180.00View SEC Filing  
6/14/2017James E FlynnInsiderSell110,447$6.39$705,756.33View SEC Filing  
6/13/2017James E FlynnMajor ShareholderSell32,447$6.59$213,825.73View SEC Filing  
6/12/2017James E FlynnMajor ShareholderSell10,000$6.74$67,400.00View SEC Filing  
6/8/2017James E FlynnInsiderSell62,868$7.06$443,848.08View SEC Filing  
5/12/2017Stonepine Capital Management,Major ShareholderSell510,000$7.40$3,774,000.00View SEC Filing  
5/11/2017Stonepine Capital Management,Major ShareholderSell244,629$7.65$1,871,411.85View SEC Filing  
5/4/2017Stonepine Capital Management,Major ShareholderSell217,308$7.70$1,673,271.60View SEC Filing  
3/16/2017Scp Vitalife Partners Ii LpMajor ShareholderSell44,977$8.00$359,816.002,276,571View SEC Filing  
2/17/2017Scp Vitalife Partners Ii LpMajor ShareholderSell9,983$7.59$75,770.972,292,899View SEC Filing  
2/16/2017Scp Vitalife Partners (Israel)Major ShareholderSell4,030$7.89$31,796.70772,714View SEC Filing  
12/16/2016Karen FlynnDirectorBuy800$6.71$5,368.00800View SEC Filing  
12/15/2016Alfred AltomariDirectorBuy1,500$6.55$9,825.001,500View SEC Filing  
12/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy650,000$6.00$3,900,000.00View SEC Filing  
8/16/2016Healthcare Master Fun BroadfinMajor ShareholderBuy390,000$7.50$2,925,000.00View SEC Filing  
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.001,000View SEC Filing  
5/23/2016Randall MackVPBuy2,000$6.30$12,600.002,000View SEC Filing  
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90776,131View SEC Filing  
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60783,642View SEC Filing  
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.202,340View SEC Filing  
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.002,349,511View SEC Filing  
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00788,847View SEC Filing  
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Recro Pharma (NASDAQ REPH) News Headlines

Source:
DateHeadline
Recro Pharma (REPH) Given a $9.00 Price Target by Roth Capital AnalystsRecro Pharma (REPH) Given a $9.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - May 27 at 9:27 AM
Recro Pharma: Breaking UpdateRecro Pharma: Breaking Update
seekingalpha.com - May 26 at 8:28 AM
FDA rejects Recro Pharma new drug application for a non-opioid pain medicineFDA rejects Recro Pharma new drug application for a non-opioid pain medicine
www.bizjournals.com - May 26 at 8:28 AM
National Securities Downgrades Recro Pharma (REPH) to SellNational Securities Downgrades Recro Pharma (REPH) to Sell
www.streetinsider.com - May 25 at 5:34 PM
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Recro Pharma, Inc.SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Recro Pharma, Inc.
finance.yahoo.com - May 25 at 5:34 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Recro Pharma, Inc. - REPHSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Recro Pharma, Inc. - REPH
finance.yahoo.com - May 25 at 5:34 PM
Recro Pharma (REPH) Given a $18.00 Price Target by Oppenheimer AnalystsRecro Pharma (REPH) Given a $18.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 25 at 2:39 PM
Recro Pharma (REPH) Announces CRL from FDA for IV meloxicam NDARecro Pharma (REPH) Announces CRL from FDA for IV meloxicam NDA
www.streetinsider.com - May 25 at 8:30 AM
Today’s Research Reports on Stocks to Watch: Recro Pharma and Stellar BiotechnologiesToday’s Research Reports on Stocks to Watch: Recro Pharma and Stellar Biotechnologies
finance.yahoo.com - May 25 at 8:30 AM
Healthcare Master Fun Broadfin Sells 188,000 Shares of Recro Pharma (REPH) StockHealthcare Master Fun Broadfin Sells 188,000 Shares of Recro Pharma (REPH) Stock
www.americanbankingnews.com - May 24 at 7:17 PM
Recro Pharma (REPH) Given Consensus Rating of "Buy" by BrokeragesRecro Pharma (REPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 5:37 PM
Deutsche Bank, Recro Pharma Drop into Thursday’s 52-Week Low ClubDeutsche Bank, Recro Pharma Drop into Thursday’s 52-Week Low Club
247wallst.com - May 24 at 5:26 PM
Recro Pharma (REPH) PT Lowered to $9.00Recro Pharma (REPH) PT Lowered to $9.00
www.americanbankingnews.com - May 24 at 1:27 PM
Janney Montgomery Scott Reaffirms Fair Value Rating for Recro Pharma (REPH)Janney Montgomery Scott Reaffirms Fair Value Rating for Recro Pharma (REPH)
www.americanbankingnews.com - May 24 at 1:27 PM
FDA Declines Recros IV Meloxicam ApplicationFDA Declines Recro's IV Meloxicam Application
feeds.benzinga.com - May 24 at 10:42 AM
FDA rejects Recro Pharmas marketing application for IV meloxicamFDA rejects Recro Pharma's marketing application for IV meloxicam
seekingalpha.com - May 24 at 8:33 AM
FDA declines to approve Recro Pharmas non-opioid pain shotFDA declines to approve Recro Pharma's non-opioid pain shot
finance.yahoo.com - May 24 at 8:33 AM
Recro Pharma Receives Complete Response Letter from the FDARecro Pharma Receives Complete Response Letter from the FDA
finance.yahoo.com - May 24 at 8:33 AM
Recro Pharmas non-opioid pain shot fails to get approval from FDARecro Pharma's non-opioid pain shot fails to get approval from FDA
finance.yahoo.com - May 24 at 8:33 AM
An Ear To The Pharma: 11 Stocks To Watch (DOVA, SESN, URGN…)An Ear To The Pharma: 11 Stocks To Watch (DOVA, SESN, URGN…)
www.nasdaq.com - May 19 at 8:27 AM
Zacks: Brokerages Anticipate Recro Pharma (REPH) Will Post Quarterly Sales of $16.89 MillionZacks: Brokerages Anticipate Recro Pharma (REPH) Will Post Quarterly Sales of $16.89 Million
www.americanbankingnews.com - May 18 at 5:39 AM
-$1.68 EPS Expected for Recro Pharma (REPH) This Quarter-$1.68 EPS Expected for Recro Pharma (REPH) This Quarter
www.americanbankingnews.com - May 16 at 3:12 AM
Recro Pharma (REPH) Downgraded by Zacks Investment ResearchRecro Pharma (REPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:39 PM
Piper Jaffray Comments on Recro Pharmas Q2 2018 Earnings (REPH)Piper Jaffray Comments on Recro Pharma's Q2 2018 Earnings (REPH)
www.americanbankingnews.com - May 14 at 1:44 AM
Recro Pharma (REPH) Issues Quarterly  Earnings Results, Beats Expectations By $0.03 EPSRecro Pharma (REPH) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 10 at 9:53 PM
Edited Transcript of REPH earnings conference call or presentation 9-May-18 12:00pm GMTEdited Transcript of REPH earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 8:39 AM
Recro Pharmas (REPH) CEO Gerri Henwood on Q1 2018 Results - Earnings Call TranscriptRecro Pharma's (REPH) CEO Gerri Henwood on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:19 PM
Recro Pharma Reports First Quarter 2018 Financial ResultsRecro Pharma Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 8:35 AM
Recro Pharma: 1Q Earnings SnapshotRecro Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:35 AM
Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018
finance.yahoo.com - May 2 at 8:36 AM
Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual MeetingRecro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
finance.yahoo.com - April 30 at 8:38 AM
$17.32 Million in Sales Expected for Recro Pharma (REPH) This Quarter$17.32 Million in Sales Expected for Recro Pharma (REPH) This Quarter
www.americanbankingnews.com - April 30 at 2:58 AM
Recro Pharma (REPH) Given Average Rating of "Buy" by BrokeragesRecro Pharma (REPH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 5:41 PM
Recro Pharma (REPH) Expected to Announce Earnings of -$0.68 Per ShareRecro Pharma (REPH) Expected to Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - April 28 at 3:14 PM
Berenberg Starts Recro Pharma (REPH) at BuyBerenberg Starts Recro Pharma (REPH) at Buy
www.streetinsider.com - April 20 at 5:11 PM
Recro Pharma (REPH) Now Covered by Analysts at Berenberg BankRecro Pharma (REPH) Now Covered by Analysts at Berenberg Bank
www.americanbankingnews.com - April 19 at 11:46 AM
Recro Pharma (REPH) Downgraded to "Hold" at Zacks Investment ResearchRecro Pharma (REPH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 4:44 PM
Recro Pharma (REPH) Rating Increased to Buy at ValuEngineRecro Pharma (REPH) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 18 at 1:24 PM
Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine MeetingRecro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting
feeds.benzinga.com - April 16 at 7:46 AM
Zacks: Brokerages Expect Recro Pharma Inc (REPH) Will Announce Quarterly Sales of $17.32 MillionZacks: Brokerages Expect Recro Pharma Inc (REPH) Will Announce Quarterly Sales of $17.32 Million
www.americanbankingnews.com - April 13 at 2:35 AM
 Analysts Expect Recro Pharma Inc (REPH) Will Post Earnings of -$0.68 Per Share Analysts Expect Recro Pharma Inc (REPH) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - April 11 at 3:10 PM
Exclusive: Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO BusinessExclusive: Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business
www.benzinga.com - April 7 at 4:20 PM
Recro Pharma (REPH) Earns Buy Rating from OppenheimerRecro Pharma (REPH) Earns Buy Rating from Oppenheimer
www.americanbankingnews.com - April 6 at 11:07 AM
Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO BusinessRecro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business
www.benzinga.com - April 5 at 5:06 PM
Recro Pharma Inc (REPH) Receives Consensus Recommendation of "Buy" from AnalystsRecro Pharma Inc (REPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 5:34 PM
Short Interest in Recro Pharma Inc (REPH) Decreases By 23.2%Short Interest in Recro Pharma Inc (REPH) Decreases By 23.2%
www.americanbankingnews.com - March 31 at 1:45 AM
Zacks Investment Research Lowers Recro Pharma (REPH) to SellZacks Investment Research Lowers Recro Pharma (REPH) to Sell
www.americanbankingnews.com - March 29 at 1:58 PM
Active-Investors: Wired News - Recro Pharma Publishes Data from Phase-III Trial for IV MeloxicamActive-Investors: Wired News - Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam
www.finanznachrichten.de - March 29 at 8:44 AM
Wired News – Recro Pharma Publishes Data from Phase-III Trial for IV MeloxicamWired News – Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam
finance.yahoo.com - March 29 at 8:44 AM
Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of PainRecro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain
finance.yahoo.com - March 27 at 8:45 AM

SEC Filings

Recro Pharma (NASDAQ:REPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Recro Pharma (NASDAQ:REPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Recro Pharma (NASDAQ REPH) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.